FMR LLC has filed an amended Schedule 13G reporting beneficial ownership of 10,999,793 shares of Centessa Pharmaceuticals plc common stock, representing 12.2% of the class.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
FMR LLC has filed an amended Schedule 13G reporting beneficial ownership of 10,999,793 shares of Centessa Pharmaceuticals plc common stock, representing 12.2% of the class. FMR LLC holds sole voting power over 10,988,411 shares and sole dispositive power over 10,999,793 shares.
Abigail P. Johnson is also listed as a reporting person with sole dispositive power over 10,999,793 shares but no voting power. The securities are certified as acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Centessa.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How large is FMR LLC's ownership stake in Centessa Pharmaceuticals (CNTA)?
FMR LLC reports beneficial ownership of 10,999,793 shares of Centessa Pharmaceuticals common stock, representing 12.2% of the outstanding class. This gives FMR a significant institutional position in the company’s equity based on the shares reported in this Schedule 13G/A.
What voting and dispositive powers does FMR LLC report over Centessa (CNTA) shares?
FMR LLC reports sole voting power over 10,988,411 shares and sole dispositive power over 10,999,793 shares of Centessa common stock. It reports no shared voting or shared dispositive power, indicating centralized control of voting and investment decisions for this position.
What role does Abigail P. Johnson have in the Centessa (CNTA) shareholding?
Abigail P. Johnson is a reporting person with sole dispositive power over 10,999,793 shares of Centessa but no voting power. This reflects her control person status over entities holding the shares, while voting authority is reported at the FMR LLC level.
What percentage of Centessa Pharmaceuticals (CNTA) does FMR LLC report owning?
FMR LLC and Abigail P. Johnson each report beneficial ownership of 12.2% of Centessa Pharmaceuticals’ common stock. This percentage is based on their aggregated beneficial holdings of 10,999,793 shares as disclosed in the amended Schedule 13G filing.
Is FMR LLC seeking to influence control of Centessa Pharmaceuticals (CNTA)?
The filing certifies the Centessa shares were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing control of the issuer, consistent with a passive ownership intent under Schedule 13G.
On what date did the Centessa (CNTA) ownership level triggering this filing occur?
The filing lists January 30, 2026 as the Date of Event Which Requires Filing of this statement. That date reflects when the reported beneficial ownership position in Centessa’s common stock met the threshold requiring this amended Schedule 13G.
Address or principal business office or, if none, residence:
245 Summer Street, Boston, Massachusetts 02210
(c)
Citizenship:
Not applicable
(d)
Title of class of securities:
COMMON STOCK
(e)
CUSIP No.:
152309100
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
10999793.00
(b)
Percent of class:
12.2 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Please see the responses to Items 5 and 6 on the cover page.
(ii) Shared power to vote or to direct the vote:
0.00
(iii) Sole power to dispose or to direct the disposition of:
10999793.00
(iv) Shared power to dispose or to direct the disposition of:
0.00
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of CENTESSA PHARMACEUTICALS PLC. No one other person's interest in the COMMON STOCK of CENTESSA PHARMACEUTICALS PLC is more than five percent of the total outstanding COMMON STOCK.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See attached Exhibit 99.
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
FMR LLC
Signature:
Stephanie J. Brown
Name/Title:
Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:
02/05/2026
Abigail P. Johnson
Signature:
Stephanie J. Brown
Name/Title:
Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
Date:
02/05/2026
Comments accompanying signature: * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
